Company Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.
The company was founded in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Troy Wilson |
Contact Details
Address: 12730 High Bluff Drive, Suite 400 San Diego, California 92130 United States | |
| Phone | 858 500 8800 |
| Website | kuraoncology.com |
Stock Details
| Ticker Symbol | KURA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422143 |
| CUSIP Number | 50127T109 |
| ISIN Number | US50127T1097 |
| Employer ID | 61-1547851 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Kathleen Ford | Chief Operating Officer |
| Teresa Brophy Bair Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Thomas Doyle | Senior Vice President of Finance and Accounting |
| Dr. Francis J. Burrows Ph.D. | Chief Scientific Officer |
| Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing and Supply Chain |
| Maureen Clancy M.B.A. | Vice President and Global Head of Program Leadership and Project Management |
| Dr. Mollie Leoni M.D. | Chief Medical Officer |
| Brian T. Powl M.B.A., M.S. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 8-K | Current Report |
| Jan 8, 2025 | SCHEDULE 13G | Filing |
| Jan 6, 2025 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |